BLU-808

Phase 2Small molecule

BBlueprint Medicines

BLU-808 is one of 2 small molecule programs targeting Chronic Inducible Urticaria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inducible UrticariaActive, not recruiting

Chronic Inducible UrticariaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Chronic Inducible Urticaria

#DrugCompanyPhaseTrials

Rhapsido

Novartis

Phase 3

1 2

BLU-808

BBlueprint Medicines

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Chronic Inducible Urticaria

NCT06931405

Clinical

Trials by Indication[1]

Adult1 trial

Study of BLU-808 in Healthy Adult Participants

Completed·BBlueprint Medicines·Phase 1·NCT06948032·95 enrolled

Allergic Rhinoconjunctivitis1 trial

A Phase 2a Randomized Double-blinded Placebo Controlled Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Clinical Activity of BLU-808, a Wild-type KIT Inhibitor, in Participants With Ragweed (Ambrosia Artemisiifolia)-Induced Allergic Rhinoconjunctivitis

Completed·BBlueprint Medicines·Phase 2·NCT06922448·21 enrolled

Chronic Inducible Urticaria1 trial

A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

Active, not recruiting·BBlueprint Medicines·Phase 2·NCT06931405·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BLU-808. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BLU-808 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BLU-808. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Blueprint Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBlueprint Medicines

BLU-808

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Adult1 trial

Allergic Rhinoconjunctivitis1 trial

Chronic Inducible Urticaria1 trial

References

Drug Info

Quick Facts

Related News